Pharmaceuticals

WECOME

WECOME released FY2025 Q4 earnings on April 28 After-Market (BJT), actual revenue CNY 73.95 M, actual EPS CNY -0.7144

WECOME released FY2025 earnings on April 28 After-Market (BJT), actual revenue CNY 225.27 M, actual EPS CNY -1.57

WECOME released FY2026 Q1 earnings on April 28 After-Market (BJT), actual revenue CNY 69.66 M, actual EPS CNY 0.012

WECOME to Release FY2026 Q1 Earnings on April 29 After-Market BJT

WECOME to Release FY2025 Earnings Report on April 29 After-Market (BJT)

WECOME released FY2025 9 Months Earnings on October 29 After-Market (BJT), actual revenue CNY 151.32 M, actual EPS CNY -0.8472

WECOME released FY2025 Q3 earnings on October 29 After-Market (BJT), actual revenue CNY 36.75 M, actual EPS CNY -0.4119

WECOME to Release FY2025 Q3 Earnings on October 30 After-Market (BJT)

WECOME released FY2025 Q2 earnings on August 27 After-Market BJT, actual revenue CNY 44.79 M, actual EPS CNY -0.3652

WECOME released FY2025 Semi-Annual Earnings on August 27 After-Market (BJT), actual revenue CNY 114.57 M, actual EPS CNY -0.4435

WECOME to Release FY2025 Semi-Annual Earnings on August 29, 2025 (BJT)

Weikang Pharmaceutical Receives Acceptance Notice for Vitamin K1 Drop Application

Wekang Pharmaceutical Fined for Failure to Disclose Related Party Fund Usage

WECOME released FY2024 Q4 earnings on April 28 After-Market (BJT), actual revenue CNY -19.65 M, actual EPS CNY -1.3137

WECOME released FY2025 Q1 earnings on April 28 After-Market BJT, actual revenue CNY 69.78 M, actual EPS CNY -0.07

WECOME released FY2024 earnings on April 28 After-Market (BJT), actual revenue CNY 351.2 M, actual EPS CNY -1.03

WECOME FY2025 Q1 Earnings Release Scheduled for April 25 After-Market BJT

WECOME FY2024 Annual Earnings Release Scheduled for April 25, 2025, After-Market BJT

Weikang Pharmaceutical Obtains Registration Approval for Erdongtang Granules

Weikang Pharmaceutical Selected in National Chinese Medicine Procurement Alliance Centralized Bulk Procurement

300878

688221

600513

688443

688091

The A-share innovative drug sector surged in the afternoon, with WECOME rising over 15%, Frontier Biotechnologies and SHANGHAI YIZHONG rising over 10%, and JLPC, Hongbo Pharmaceutical, Genrix Bio, and Chengda Pharmaceutical following suit

Wallstreetcn

Froniter Biotechnologies

JLPC

Genrix Bio

SHANGHAI YIZHONG

300497

002940

688336

002370

A-share innovative drug concept stocks are active again, Sunshine Guojian Pharmaceutical rose over 10% to a new high, Yatai Pharm had two consecutive limit-ups, WECOME rose over 10%, and Baicheng Pharmaceutical, ALK, and Fushine followed suit

Zhitong

Fushine

Sunshine Guojian Pharmaceutical

Yatai pharm

According to the Zhitong Finance APP, WECOME released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 151 million yuan, a year-on-year decrease of 59.20%. The net loss attributable to shareholders of the listed company was 124 million yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 122 million yuan. The basic loss per share was 0.8554 yuan

WECOME Pharmaceuticals released its performance for the first three quarters, with a net loss attributable to the parent company of 124 million yuan

Kangbaijia Pharmaceutical Group has initiated IPO counseling and plans to complete its listing in 2026. As a chain pharmacy with over 2,000 stores, Kangbaijia has a presence in Fujian, Zhejiang, Jiangxi, and other regions. Despite facing market pressures and regulatory challenges, Kangbaijia continues to expand its market share through acquisitions. After acquiring a subsidiary of WECOME in 2024, its market footprint extends into Zhejiang. Investment should be approached with caution, and market risks must be considered

The A-share chain pharmacy IPO project is here: Kangbaijia starts counseling

The Zhejiang Securities Regulatory Bureau has issued a warning letter to Minsheng Securities and its sponsoring representatives Ren Shaozhong and Zhong Desong. Minsheng Securities failed to adequately pay attention to the delays in construction projects and insufficient verification procedures during the continuous supervision of the initial public offering of Zhejiang WECOME, violating relevant management regulations

The Zhejiang Securities Regulatory Bureau has issued warning letters to Minsheng Securities, Ren Shaozhong, and Zhong Desong

300683

002004

688098

300204

603367

Innovative drug concept stocks continue to be active, HUAPONT LIFE SCIENCES hits the limit up, Shen Lian Biomedical, Staidson BioPharm, CISEN, and WECOME follow suit

HITECK

HUAPONT LIFE SCIENCES

Shen Lian Biomedical

Staidson BioPharm

CISEN

Innovative drug concept stocks continue to be active, HUAPONT LIFE SCIENCES hits the limit up

WECOME and Yingkerui Pharmaceutical Co., Ltd. jointly applied for the Phase III clinical trial of Huangjia Soft Liver Granules. The trial aims to evaluate the efficacy and safety of Huangjia Soft Liver Granules in treating chronic hepatitis B virus-related liver fibrosis. The Phase II trial has been completed, showing good clinical efficacy and safety. This trial will include 480 participants and will adopt a randomized, double-blind, placebo-controlled design

WECOME: Huangjia Soft Liver Granules initiate Phase III clinical trials

688062

300584

000661

300685

Innovative drug concept stocks are repeatedly active, Mabwell and BeiGene hit new highs during the session, CCHT has two consecutive limit-ups, AmoyDx and Hicin Pharmaceutical rose over 10%, and WECOME, Warner Pharmaceuticals, Nanxin Pharmaceutical, and Betta Pharmaceuticals followed suit

Mabwell

Hicin Pharmaceutical

CCHT

AmoyDx

Innovative drug concept stocks are repeatedly active, CCHT has two consecutive limit-ups

On August 8th, WECOME announced that the company's board of directors received a written resignation letter from the company's board secretary and director, Zhu Ting, on the same day. Zhu Ting applied to resign from the position of board secretary for personal reasons, and the resignation will take effect from the date it is delivered to the company's board of directors. After resigning from the above position, Zhu Ting will continue to serve as a director of the company. To ensure the normal operation of the company's information disclosure and other work, the company's chairman, Liu Yang, will temporarily perform the duties of the board secretary until the new board secretary takes office

WECOME: Board Secretary Zhu Ting resigns for personal reasons

Today, the Shanghai Composite Index closed down 0.19%, while the Shenzhen Component Index and the ChiNext Index fell 0.15% and 0.16%, respectively. The North Exchange 50 Index rose slightly by 0.11%. The market turnover was 1,008.1 billion yuan, a decrease of 149.7 billion yuan from the previous day, with over 2,100 stocks declining. The traditional Chinese medicine and photovoltaic equipment sectors performed strongly, with Bio Valley rising over 25% and WECOME hitting the daily limit. The military industry and film theater sectors, however, experienced adjustments, with ST Emergency hitting the daily limit down and Golden Eagle Media falling over 7%

Midday Review: The Shanghai Composite Index fluctuated narrowly and closed down 0.19%, with the pharmaceutical sector strengthening across the board

WECOME(300878.SZ)